PT-141 (Bremelanotide)
Non-selective melanocortin agonist (MC3R/MC4R) in the central nervous system. Induces sexual arousal via neural pathways, independent of the vascular system.
- Treatment of hypoactive sexual desire
- Increased libido (both sexes)
- Erection via the central nervous system (non-hemodynamic)Treatment of hypoactive sexual desire
- Erection via the central nervous system (non-hemodynamic)
- Nausea (very common), flushing, headache.
PT-141, or Bremelanotide, is a synthetic peptide derived from Melanotan 2, which acts as a non-selective agonist of melanocortin receptors, specifically targeting the central nervous system to regulate sexual function.
READ MORE
What it is (in plain language)
- Unlike Viagra, which acts on the blood vessels, PT-141 acts directly on the brain. It 'switches on' sexual desire at a neurological level. It is used to treat erectile dysfunction in men and hypoactive sexual desire disorder in women, and is one of the few substances approved for this purpose.
Why do you appear online so much
- It is widely discussed as the 'definitive' solution for cases of low libido that don't respond to hormonal therapies. It has become famous for inducing a powerful sexual response without affecting blood pressure in a dangerous way, although it can cause initial nausea.
How it is framed today (pragmatic view)
- 1) Evidence: Approved by the FDA (Vyleesi) for clinical use. 2) Purpose: Restoration of libido and neurological sexual function. 3) Risk: Nausea and facial flushing are common; blood pressure should be monitored in sensitive individuals.
How to use this form
- See the timing protocols in the dosage section to optimise the efficacy window.
- Quick profile (curated by Subject 157)
- Class: Other
- Status: Verified
- Use case: Other
- Route: Injectable
- Tags: Injectable|Libido|Approved
- Half-life: ~2-3 Hours
- Start: 30min - 2h
- Duration: ~8-12 hours
- Mechanism (high level)
Non-selective melanocortin agonist (MC3R/MC4R) in the central nervous system. Induces sexual arousal via neural pathways, independent of the vascular system.
- Evidence (what the literature covers)
RESEARCH RANGE (Clinical, Non-prescriptive):
Approved by the FDA (Vyleesi) in doses of 1.75mg SC.
Level of Evidence: A (FDA Approved).
- Safety and harm-reduction (non-prescriptive)
Risks: Nausea (very common), flushing, headache.
Interactions: Naltrexone (reduces oral absorption).
- References (anchors)
- Clayton, A. H. (2015) - PT-141 (Bremelanotide) phase 3 trials - https://doi.org/10.1097/AOG.0000000000001114 | PubMed:26551187
- Molinoff, P. B. (2009) - PT-141 and female sexual arousal - https://doi.org/10.1210/en.2009-1217 | PubMed:20392823
Note: Educational/research content. Does not constitute medical advice, diagnosis or prescription.
EN 
PT 
FR 
ES 
DE 
IT 
PL